2022 - Research.com Medicine in South Korea Leader Award
Kwang Hyub Han spends much of his time researching Internal medicine, Gastroenterology, Hepatocellular carcinoma, Cirrhosis and Hepatitis B. His Internal medicine research is multidisciplinary, incorporating perspectives in Entecavir, HBeAg and Surgery. Kwang Hyub Han has included themes like Fibrosis, Pathology, Liver biopsy and Hepatitis B virus in his Gastroenterology study.
Kwang Hyub Han has researched Hepatocellular carcinoma in several fields, including Carcinoma, Radiology and Hazard ratio. His Cirrhosis research includes elements of Stage and Predictive value of tests. His biological study deals with issues like Hepatitis C, which deal with fields such as Epidemiology.
Kwang Hyub Han mainly focuses on Internal medicine, Gastroenterology, Hepatocellular carcinoma, Cirrhosis and Hepatitis B virus. The various areas that he examines in his Internal medicine study include Surgery and Oncology. His work deals with themes such as Chronic hepatitis, Liver biopsy, Hazard ratio, Entecavir and Fibrosis, which intersect with Gastroenterology.
His work carried out in the field of Hepatocellular carcinoma brings together such families of science as Radiology, Radiation therapy, Carcinoma and Retrospective cohort study. His Cirrhosis study incorporates themes from Receiver operating characteristic, Liver disease, Ascites and Pathology. His Transient elastography research incorporates elements of Liver stiffness and Confidence interval.
His scientific interests lie mostly in Internal medicine, Hepatocellular carcinoma, Gastroenterology, In patient and Cirrhosis. His Internal medicine research integrates issues from Entecavir, Chronic hepatitis and Hepatitis B virus. His research integrates issues of Radiology, Radiation therapy, Carcinoma and Oncology in his study of Hepatocellular carcinoma.
The study incorporates disciplines such as Hepatitis B, Population study, Multivariate analysis, Antiviral therapy and Fibrosis in addition to Gastroenterology. The Hepatitis B study which covers Univariate analysis that intersects with Steatosis. His Cirrhosis study also includes
His primary areas of investigation include Hepatocellular carcinoma, Internal medicine, Gastroenterology, Entecavir and Hazard ratio. His biological study spans a wide range of topics, including Carcinoma, Radiology, Overall survival and Cohort. The concepts of his Internal medicine study are interwoven with issues in Oncology and Hepatitis B virus.
His Gastroenterology research is multidisciplinary, relying on both Hepatitis B, External validation and Incidence, Cumulative incidence. Kwang Hyub Han usually deals with Hepatitis B and limits it to topics linked to Univariate analysis and Magnetic resonance imaging and Hyperintensity. His study in the field of Hepatic fibrosis also crosses realms of Hepatocyte.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting Tsung Chang;Robert G. Gish;Robert De Man;Adrian Gadano.
The New England Journal of Medicine (2006)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han.
The Lancet (2018)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.
Yun-Fan Liaw;Nancy H. L. Leung;Jia-Horng Kao;Teerha Piratvisuth.
Hepatology International (2008)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
Yun Fan Liaw;Jia Horng Kao;Teerha Piratvisuth;Henry Lik Yuen Chan.
Hepatology International (2012)
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen.
Hepatology International (2010)
Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
Ting Tsung Chang;Yun Fan Liaw;Shun Sheng Wu;Eugene Schiff.
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo.
Hepatology International (2017)
Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study
Hyeon Chang Kim;Chung Mo Nam;Sun Ha Jee;Kwang Hyub Han.
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
William Sievert;Ibrahim Altraif;Homie A. Razavi;Ayman Abdo.
Liver International (2011)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix;Tadatoshi Takayama;Vincenzo Mazzaferro;Gar Yang Chau.
Lancet Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: